$ATAI
ATAI Life Sciences NV

2023 Q4 Form 10-Q Financial Statement

#000095017023063730 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $18.00K $87.00K
YoY Change -52.63% 262.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.42M $13.63M
YoY Change 23.5% -29.81%
% of Gross Profit
Research & Development $14.16M $13.29M
YoY Change -35.29% -30.16%
% of Gross Profit
Depreciation & Amortization $99.00K $80.00K
YoY Change 86.79% 122.22%
% of Gross Profit
Operating Expenses $33.58M $26.92M
YoY Change -10.7% -29.98%
Operating Profit -$26.83M
YoY Change -30.16%
Interest Expense -$69.35M $686.0K
YoY Change 1466.88% -85.14%
% of Operating Profit
Other Income/Expense, Net $85.54M $70.68M
YoY Change 3103.82% 1236.38%
Pretax Income -$18.32M $43.85M
YoY Change -53.41% -232.33%
Income Tax $428.0K $200.0K
% Of Pretax Income 0.46%
Net Earnings -$18.29M $44.24M
YoY Change -59.36% -230.56%
Net Earnings / Revenue -101622.22% 50855.17%
Basic Earnings Per Share $0.28
Diluted Earnings Per Share -$0.11 $0.25
COMMON SHARES
Basic Shares Outstanding 166.0M 166.0M
Diluted Shares Outstanding 177.6M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $179.3M $209.0M
YoY Change -34.36% -31.26%
Cash & Equivalents $45.00M $76.50M
Short-Term Investments $134.2M $132.5M
Other Short-Term Assets $846.0K $638.0K
YoY Change -51.52% -53.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $185.6M $215.8M
YoY Change -35.37% -32.02%
LONG-TERM ASSETS
Property, Plant & Equipment $981.0K $992.0K
YoY Change 5.71% 36.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $2.720M $3.107M
YoY Change -18.83% -64.44%
Total Long-Term Assets $107.9M $92.40M
YoY Change 489.67% 267.89%
TOTAL ASSETS
Total Short-Term Assets $185.6M $215.8M
Total Long-Term Assets $107.9M $92.40M
Total Assets $293.5M $308.2M
YoY Change -3.92% -10.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.589M $5.506M
YoY Change 91.29% 56.82%
Accrued Expenses $15.26M $13.01M
YoY Change -11.85% -41.25%
Deferred Revenue
YoY Change
Short-Term Debt $109.2M $132.5M
YoY Change 32.36% -17.96%
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $20.12M $19.70M
YoY Change 1.12% -24.0%
LONG-TERM LIABILITIES
Long-Term Debt $17.88M $15.40M
YoY Change 18.26% 2.66%
Other Long-Term Liabilities $7.918M $2.736M
YoY Change 113.54% -25.95%
Total Long-Term Liabilities $7.918M $2.736M
YoY Change 113.54% -25.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.12M $19.70M
Total Long-Term Liabilities $7.918M $2.736M
Total Liabilities $49.16M $39.71M
YoY Change 23.91% -14.64%
SHAREHOLDERS EQUITY
Retained Earnings -$550.9M -$532.6M
YoY Change 7.98% 14.49%
Common Stock $18.57M $18.57M
YoY Change 0.06% 0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $243.0M $266.3M
YoY Change
Total Liabilities & Shareholders Equity $293.5M $308.2M
YoY Change -3.92% -10.03%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$18.29M $44.24M
YoY Change -59.36% -230.56%
Depreciation, Depletion And Amortization $99.00K $80.00K
YoY Change 86.79% 122.22%
Cash From Operating Activities -$21.96M -$18.43M
YoY Change -28.02% -34.28%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -91.03% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$805.0K -$46.48M
YoY Change -101.0% -169.81%
Cash From Investing Activities -$825.0K -$46.48M
YoY Change -101.03% -170.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.465M 0.000
YoY Change 818.11% -100.0%
NET CHANGE
Cash From Operating Activities -21.96M -18.43M
Cash From Investing Activities -825.0K -46.48M
Cash From Financing Activities -8.465M 0.000
Net Change In Cash -31.25M -64.91M
YoY Change -164.26% -212.33%
FREE CASH FLOW
Cash From Operating Activities -$21.96M -$18.43M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$21.98M -$18.43M
YoY Change -28.48% -33.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
dei Entity Central Index Key
EntityCentralIndexKey
0001840904
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40493
dei Entity Registrant Name
EntityRegistrantName
ATAI Life Sciences N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
ATAI Life Sciences N.V.
dei Entity Address Address Line2
EntityAddressAddressLine2
Wallstraße 16, 10179
dei Entity Address City Or Town
EntityAddressCityOrTown
Berlin
dei Entity Address Country
EntityAddressCountry
DE
dei City Area Code
CityAreaCode
49 89
dei Local Phone Number
LocalPhoneNumber
2153 9035
dei Security12b Title
Security12bTitle
Common shares, par value €0.10 per share
dei Trading Symbol
TradingSymbol
ATAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
166010476
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76492000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190613000
CY2023Q3 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
132502000
CY2022Q4 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
82496000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6831000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
215825000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
287145000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
992000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
928000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1258000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q3 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
71511000
CY2022Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
0
CY2023Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
3659000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
CY2023Q3 us-gaap Notes Receivable By Owner To Limited Liability Company Llc
NotesReceivableByOwnerToLimitedLiabilityCompanyLLC
1519000
CY2022Q4 us-gaap Notes Receivable By Owner To Limited Liability Company Llc
NotesReceivableByOwnerToLimitedLiabilityCompanyLLC
0
CY2023Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
10349000
CY2022Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
7262000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3107000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3125000
CY2023Q3 us-gaap Assets
Assets
308220000
CY2022Q4 us-gaap Assets
Assets
305441000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5506000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2399000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13008000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
889000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19695000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19897000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
900000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
953000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1011000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q3 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
410000
CY2022Q4 atai Convertible Promissory Notes Related Parties Transaction
ConvertiblePromissoryNotesRelatedPartiesTransaction
415000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
14956000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2736000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3664000
CY2023Q3 us-gaap Liabilities
Liabilities
39708000
CY2022Q4 us-gaap Liabilities
Liabilities
39675000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166010476
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166010476
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
165935914
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
165935914
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
18571000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18562000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
799461000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
774092000
CY2023Q3 atai Share Subscription Receivable
ShareSubscriptionReceivable
0
CY2022Q4 atai Share Subscription Receivable
ShareSubscriptionReceivable
-24000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19109000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21702000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-532647000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510188000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
266276000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260740000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
2236000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
268512000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
308220000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305441000
CY2023Q3 us-gaap Revenues
Revenues
87000
CY2022Q3 us-gaap Revenues
Revenues
24000
us-gaap Revenues
Revenues
296000
us-gaap Revenues
Revenues
195000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13290000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
19028000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48047000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
52437000
CY2023Q3 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
CY2022Q3 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
357000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13631000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19419000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44159000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54623000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26921000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
38447000
us-gaap Operating Expenses
OperatingExpenses
92206000
us-gaap Operating Expenses
OperatingExpenses
107417000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26834000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38423000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91910000
us-gaap Operating Income Loss
OperatingIncomeLoss
-107222000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
612000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
145000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1191000
us-gaap Investment Income Interest
InvestmentIncomeInterest
361000
CY2023Q3 us-gaap Interest Expense
InterestExpense
686000
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1965000
us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
58000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-430000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-53000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-525000
CY2023Q3 atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
0
CY2022Q3 atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
0
atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
0
atai Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
53000
CY2023Q3 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
1832000
CY2022Q3 atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
344000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
3322000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-981000
CY2023Q3 atai Change In Fair Value Of Other Investments Held At Fair Value
ChangeInFairValueOfOtherInvestmentsHeldAtFairValue
69014000
CY2022Q3 atai Change In Fair Value Of Other Investments Held At Fair Value
ChangeInFairValueOfOtherInvestmentsHeldAtFairValue
0
atai Change In Fair Value Of Other Investments Held At Fair Value
ChangeInFairValueOfOtherInvestmentsHeldAtFairValue
69014000
atai Change In Fair Value Of Other Investments Held At Fair Value
ChangeInFairValueOfOtherInvestmentsHeldAtFairValue
0
CY2023Q3 atai Change In Fair Value Of Convertible Notes Receivable Related Party
ChangeInFairValueOfConvertibleNotesReceivableRelatedParty
22000
CY2022Q3 atai Change In Fair Value Of Convertible Notes Receivable Related Party
ChangeInFairValueOfConvertibleNotesReceivableRelatedParty
0
atai Change In Fair Value Of Convertible Notes Receivable Related Party
ChangeInFairValueOfConvertibleNotesReceivableRelatedParty
22000
atai Change In Fair Value Of Convertible Notes Receivable Related Party
ChangeInFairValueOfConvertibleNotesReceivableRelatedParty
0
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
253000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4470000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-593000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11515000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-308000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70681000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5289000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70944000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11361000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
43847000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33134000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20966000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-95861000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
238000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
135000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
588000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
227000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-238000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2432000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3199000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-14680000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35701000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Profit Loss
ProfitLoss
-110768000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1814000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3394000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
44244000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-33887000
us-gaap Net Income Loss
NetIncomeLoss
-21932000
us-gaap Net Income Loss
NetIncomeLoss
-107374000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
156607468
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155793601
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154713922
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177565973
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
156607468
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793601
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154713922
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35701000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Profit Loss
ProfitLoss
-110768000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1709000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4597000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2593000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17452000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
45080000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-40298000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-22160000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-128220000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
873000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1814000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2821000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3394000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
22000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
48000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
31000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
67000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-851000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1766000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2790000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-3327000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45931000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38532000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19370000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124893000
CY2022Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
265766000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181000
CY2023Q1 atai Settlement Of Issuance Of Common Shares Value
SettlementOfIssuanceOfCommonSharesValue
24000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8662000
CY2023Q1 atai Adjustment To Accumulated Deficit Pursuant To Adoption Of Asu201613
AdjustmentToAccumulatedDeficitPursuantToAdoptionOfAsu201613
-526000
CY2023Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
887000
CY2023Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-34354000
CY2023Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
240640000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8762000
CY2023Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
6000
CY2023Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-33771000
CY2023Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
215637000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8253000
CY2023Q3 atai Additional Paid In Capital Upon Acquisition Of Variable Interest Entity
AdditionalPaidInCapitalUponAcquisitionOfVariableInterestEntity
-480000
CY2023Q3 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
1731000
CY2023Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
43371000
CY2023Q3 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
268512000
CY2021Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
385959000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
132000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10208000
CY2022Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4384000
CY2022Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37558000
CY2022Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
354357000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1140000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
CY2022Q2 atai Issuance Of Subsidiary Preferred Shares
IssuanceOfSubsidiaryPreferredShares
600000
CY2022Q2 atai Issuance Of Subsidiary Common Shares
IssuanceOfSubsidiaryCommonShares
357000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9511000
CY2022Q2 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-8452000
CY2022Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37509000
CY2022Q2 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
320122000
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3773000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1921000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10515000
CY2022Q3 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4549000
CY2022Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-35701000
CY2022Q3 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
296081000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Profit Loss
ProfitLoss
-110768000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
115000
atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
297000
atai Change In Right Of Use Asset
ChangeInRightOfUseAsset
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
272000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-53000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-525000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
3322000
atai Change In Fair Value Of Securities Carried At Fair Value
ChangeInFairValueOfSecuritiesCarriedAtFairValue
-981000
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
0
atai Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
53000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
69014000
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0
atai Change In Fair Value Of Convertible Notes Receivable Related Party
ChangeInFairValueOfConvertibleNotesReceivableRelatedParty
22000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
3199000
atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
14680000
us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
0
us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
357000
us-gaap Share Based Compensation
ShareBasedCompensation
25677000
us-gaap Share Based Compensation
ShareBasedCompensation
30235000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-555000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
9536000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-42000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-158000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6716000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1778000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3096000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2436000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4980000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4924000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62156000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73962000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
251000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
631000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
322000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
170000
atai Cash Paid For Other Investments Held At Fair Value
CashPaidForOtherInvestmentsHeldAtFairValue
724000
atai Cash Paid For Other Investments Held At Fair Value
CashPaidForOtherInvestmentsHeldAtFairValue
0
atai Cash Paid For Convertible Notes Receivable Related Party
CashPaidForConvertibleNotesReceivableRelatedParty
1497000
atai Cash Paid For Convertible Notes Receivable Related Party
CashPaidForConvertibleNotesReceivableRelatedParty
0
atai Cash Paid Upon Aquisition Of Variable Interest Entity
CashPaidUponAquisitionOfVariableInterestEntity
480000
atai Cash Paid Upon Aquisition Of Variable Interest Entity
CashPaidUponAquisitionOfVariableInterestEntity
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
486000
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
atai Cash Paid For Other Investments
CashPaidForOtherInvestments
-0
atai Cash Paid For Other Investments
CashPaidForOtherInvestments
600000
atai Proceeds From Sale And Maturities Of Securities Carried At Fair Value
ProceedsFromSaleAndMaturitiesOfSecuritiesCarriedAtFairValue
-130363000
atai Proceeds From Sale And Maturities Of Securities Carried At Fair Value
ProceedsFromSaleAndMaturitiesOfSecuritiesCarriedAtFairValue
-94055000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
177047000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
256554000
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52472000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-166900000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2171000
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
0
us-gaap Proceeds From Issuance Of Trust Preferred Securities
ProceedsFromIssuanceOfTrustPreferredSecurities
600000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4635000
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
0
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
15000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
100000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
699000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21707000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
401000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-572000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-114121000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-219727000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190613000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362266000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76492000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142539000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1475000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Interest Paid Net
InterestPaidNet
1428000
us-gaap Interest Paid Net
InterestPaidNet
0
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
487000
atai Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement
IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement
0
atai Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement
IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement
357000
atai Deferred Financing Costs Included In Accounts Payable And Accrued Expenses
DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
0
atai Deferred Financing Costs Included In Accounts Payable And Accrued Expenses
DeferredFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
1046000
us-gaap Nature Of Operations
NatureOfOperations
<p id="footnotes" style="text-indent:0;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Or</span><span id="notes"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0;font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. atai is dedicated to developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0;font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">532.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, debt financings, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of September 30, 2023 will be </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76500000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
132500000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-532600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.133%;text-indent:0;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), the fair value of convertible notes receivable - related party, securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”) and noncontrolling interests recognized in acquisitions, the valuation of share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
133153000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
154830000
CY2023Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2022Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2200000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
5026000
CY2023Q1 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-1219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-8000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
3815000
CY2023Q2 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-729000
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
1000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
3087000
CY2023Q3 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
0
CY2023Q3 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-873000
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
22000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
2236000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
9051000
CY2022Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-689000
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-11000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8351000
CY2022Q2 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
957000
CY2022Q2 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-891000
CY2022Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-30000
CY2022Q2 us-gaap Minority Interest
MinorityInterest
8447000
CY2022Q3 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
0
CY2022Q3 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-1456000
CY2022Q3 atai Net Loss Attributable To Redeemable Noncontrolling Interests Common
NetLossAttributableToRedeemableNoncontrollingInterestsCommon
-358000
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
48000
CY2022Q3 us-gaap Minority Interest
MinorityInterest
6681000
CY2023Q3 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
3600000
CY2023Q3 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
10300000
CY2022Q4 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
6800000
CY2022Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
7200000
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q3 atai Other Investments Held At Fair Value
OtherInvestmentsHeldAtFairValue
71511000
CY2022Q4 atai Other Investments Held At Fair Value
OtherInvestmentsHeldAtFairValue
0
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
3659000
CY2022Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
6755000
atai Equity Method Investment Shares Transaction Date
EquityMethodInvestmentSharesTransactionDate
2026-12-31
us-gaap Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
9600000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2300000
CY2022 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
CY2023Q3 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2022Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2023Q3 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.05
CY2022Q4 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.05
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
2131000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2034000
CY2023Q3 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
2564000
CY2022Q4 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
4626000
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
1497000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
5631000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
638000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1745000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6831000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14036000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3494000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3566000
CY2023Q3 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3964000
CY2022Q4 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
5550000
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4201000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5260000
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
887000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2224000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
463000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
706000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13008000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17306000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.126
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1258000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
180000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1011000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
122000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
399000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
355000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
355000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
355000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
118000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
1704000
CY2023Q3 us-gaap Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
401000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1303000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
304000
atai Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
193000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
1356000
atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
487000
CY2023Q3 us-gaap Convertible Debt
ConvertibleDebt
410000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
415000
CY2023Q3 us-gaap Loans Held For Sale Maturity Date
LoansHeldForSaleMaturityDate
2026-08-01
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
175000000
CY2023Q3 atai Prime Rate Percent
PrimeRatePercent
0.0455
CY2023Q3 atai Accrued Interest Payable
AccruedInterestPayable
0.0855
CY2022Q3 atai Borrowing Amount Percentage
BorrowingAmountPercentage
0.33
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2023Q3 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2022Q4 atai End Of The Term Charge
EndOfTheTermCharge
1042000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-222000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-274000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-92000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-113000
CY2023Q3 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-772000
CY2022Q4 atai Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
-952000
CY2023Q3 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14956000
CY2022Q4 us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet
14702000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
14956000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
14702000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18750486
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35701000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Profit Loss
ProfitLoss
-110768000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1814000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3394000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
44244000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33887000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21932000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-107374000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155792490
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
156607468
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155793601
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154713922
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43371000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-35701000
us-gaap Profit Loss
ProfitLoss
-24753000
us-gaap Profit Loss
ProfitLoss
-110768000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-873000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1814000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2821000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3394000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
44244000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33887000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21932000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-107374000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177565973
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
156607468
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155793601
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154713922
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34896194
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46782562
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
300000
atai Related Party Reservation Rate Of Common Shares For Ipo
RelatedPartyReservationRateOfCommonSharesForIpo
0.27
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
100000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
400000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
400000
CY2023Q1 atai Percentage Of Restructed Workforce
PercentageOfRestructedWorkforce
0.30
us-gaap Restructuring Costs
RestructuringCosts
3200000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
us-gaap Restructuring Costs
RestructuringCosts
3206000
atai Non Cash Impact Of Stock Based Compensation
NonCashImpactOfStockBasedCompensation
195000
us-gaap Payments For Restructuring
PaymentsForRestructuring
3011000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0

Files In Submission

Name View Source Status
0000950170-23-063730-index-headers.html Edgar Link pending
0000950170-23-063730-index.html Edgar Link pending
0000950170-23-063730.txt Edgar Link pending
0000950170-23-063730-xbrl.zip Edgar Link pending
atai-20230930.htm Edgar Link pending
atai-20230930.xsd Edgar Link pending
atai-ex10_2.htm Edgar Link pending
atai-ex31_1.htm Edgar Link pending
atai-ex31_2.htm Edgar Link pending
atai-ex32_1.htm Edgar Link pending
atai-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img105944471_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
atai-20230930_def.xml Edgar Link unprocessable
atai-20230930_cal.xml Edgar Link unprocessable
atai-20230930_lab.xml Edgar Link unprocessable
atai-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atai-20230930_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending